A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the ...

The oral medication muvalaplin may safely lower high levels of lipoprotein(a), also known as Lp(a), an independent, inherited risk factor for cardiovascular disease. Muvalaplin is a small molecule ...

Some antibiotics can cause a yeast infection. Learn more about how antibiotics cause yeast infections, risk factors for yeast infections, and how to treat and prevent them.

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developi ...

The bacterial changes also correlate with increased antibiotic resistance, highlighting the need for better targeting of ...

University of Queensland researchers have developed a new class of oral painkillers to suppress chronic abdominal pain that is based on the peptide hormone oxytocin that drives childbirth contractions ...

Patients with venous thromboembolism (VTE) initiating oral anticoagulants have an increased risk for bleeding when usi ...

American Heart Association Scientific Sessions 2024, Late Breaking Science Abstract 4170722 - A study testing a new nasal ...

Until my mid-40s, my approach to gum health was, at best, sporadic. I had always suspected that flossing was one of those ...

The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly ...